Acadia Healthcare (NASDAQ:ACHC) Issues FY 2025 Earnings Guidance

Acadia Healthcare (NASDAQ:ACHC - Get Free Report) updated its FY 2025 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of 2.500-2.800 for the period, compared to the consensus estimate of 2.66. The company issued revenue guidance of $3.3 billion-$3.4 billion, compared to the consensus revenue estimate of $3.3 billion.

Acadia Healthcare Stock Performance

NASDAQ ACHC traded down $0.71 during trading hours on Thursday, hitting $25.02. The company had a trading volume of 853,283 shares, compared to its average volume of 1,690,996. Acadia Healthcare has a fifty-two week low of $20.36 and a fifty-two week high of $82.41. The company has a quick ratio of 1.07, a current ratio of 1.07 and a debt-to-equity ratio of 0.60. The business has a fifty day simple moving average of $26.34 and a 200-day simple moving average of $36.01. The firm has a market cap of $2.30 billion, a P/E ratio of 8.24, a price-to-earnings-growth ratio of 1.46 and a beta of 1.01.

Acadia Healthcare (NASDAQ:ACHC - Get Free Report) last released its earnings results on Monday, May 12th. The company reported $0.40 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.35 by $0.05. Acadia Healthcare had a return on equity of 11.12% and a net margin of 8.99%. The firm had revenue of $770.51 million for the quarter, compared to analyst estimates of $769.90 million. During the same period in the previous year, the company earned $0.84 earnings per share. Acadia Healthcare's revenue was up .3% compared to the same quarter last year. Equities analysts predict that Acadia Healthcare will post 3.38 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the company. KeyCorp decreased their price target on Acadia Healthcare from $65.00 to $55.00 and set an "overweight" rating for the company in a research report on Wednesday. Guggenheim started coverage on shares of Acadia Healthcare in a research report on Wednesday, April 9th. They issued a "buy" rating and a $36.00 target price for the company. Barclays dropped their price target on shares of Acadia Healthcare from $35.00 to $28.00 and set an "equal weight" rating on the stock in a research note on Wednesday. Royal Bank of Canada lowered their target price on Acadia Healthcare from $64.00 to $43.00 and set an "outperform" rating on the stock in a research note on Monday, March 3rd. Finally, Bank of America reduced their price target on Acadia Healthcare from $50.00 to $44.50 and set a "buy" rating for the company in a report on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $47.94.

Acadia Healthcare Company Profile

Acadia Healthcare Company, Inc provides behavioral healthcare services in the United States and Puerto Rico. The company develops and operates acute inpatient psychiatric facilities, specialty treatment facilities comprising residential recovery facilities and eating disorder facilities, comprehensive treatment centers, and residential treatment centers, as well as facilities offering outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities.